ANTX (AN2 Therapeutics) Volatility: 210.63% (As of Jul. 01, 2026)


ANTX AN2 Therapeutics Inc ANTX
22 GF Score
Price $4.70
! 4 Warning Signs
View Full Analysis

What is AN2 Therapeutics Volatility?

AN2 Therapeutics ANTX -2.69% 22 Volatility is 210.63% as of Jul. 01, 2026. GuruFocus rates ANTX with a GF Score™ of 22/100. The stock has 4 warning signs investors should review.

Volatility is a statistical measure of the dispersion of returns for a given security or market index, it shows how the price swings around its mean. The volatility here is measured as the annualized standard deviation between monthly returns from the security over the past year. In most cases, the higher the volatility, the riskier the security.

As of today (2026-07-01), AN2 Therapeutics's Volatility is 210.63%.


AN2 Therapeutics  (NAS:ANTX) Volatility Explanation

Volatility is a statistical measure of the dispersion of returns for a given security or market index. It’s often measured as standard deviation or variance of historical returns over a certain period. The volatility here is measured as the annualized standard deviation between monthly returns from the security over the past year.

Volatility reflects the uncertainty or risk of a security’s value. Generally speaking, a higher volatility suggests a higher risk, because it implies a wider fluctuation around average price. This means the price of the security can change dramatically in either direction within a short period. Conversely, a lower volatility means that the security's price is more steady, which suggests a lower risk.

Another measurement of relative volatility is Beta. Beta is a measure of systematic risk of a security or a portfolio in comparison to the market as a whole. Beta is usually compared to 1. A beta of greater than 1 indicates that the security's price will be more volatile than the market.


AN2 Therapeutics Volatility Related Terms


ANTX vs OKUR, KRRO, LENZ: Volatility Comparison

For the Biotechnology subindustry, AN2 Therapeutics's Volatility, along with its competitors' market caps and Volatility data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AN2 Therapeutics Volatility vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AN2 Therapeutics's Volatility distribution charts can be found below:

* The bar in red indicates where AN2 Therapeutics's Volatility falls into.


ANTX
22GF Score
AN2 Therapeutics Inc ANTX
Volatility is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AN2 Therapeutics  (NAS:ANTX) Volatility Calculation

The annualized volatility is calculated as following:

σA=σM * 12
= 1/(n-1) ∑(Ri - R')^2 * 12

Where: σM is the monthly volatility, n is the number of months in the period, Ri is the security's historical monthly returns and R' is the arithmetic mean of monthly returns.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Volatility →
What does a Volatility of 210.63% mean?
AN2 Therapeutics (ANTX) has a Volatility of 210.63% as of Jul. 01, 2026. Volatility is measured as the annualized standard deviation between monthly returns from the security over the past year. View historical data on AN2 Therapeutics and its competitors.
Is AN2 Therapeutics' Volatility too high?
AN2 Therapeutics' current Volatility is 210.63%. Overall, AN2 Therapeutics has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does AN2 Therapeutics' Volatility compare to OKUR and KRRO?
AN2 Therapeutics' Volatility of 210.63% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Volatility for a Biotechnology company?
A good Volatility depends on the Biotechnology industry context. However, Volatility should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Volatility mean?
A high Volatility can signal that a stock is expensive relative to its fundamentals. Volatility is measured as the annualized standard deviation between monthly returns from the security over the past year. View historical data on AN2 Therapeutics and its competitors. AN2 Therapeutics's current Volatility is 210.63%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AN2 Therapeutics stock overvalued right now?
AN2 Therapeutics (ANTX) has a current Volatility of 210.63%. The current Volatility is 210.63%. AN2 Therapeutics' overall GF Score™ is 22/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Volatility calculated?
Volatility is calculated from a company's financial statements. For AN2 Therapeutics (ANTX), the current Volatility is 210.63% as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

AN2 Therapeutics Business Description

Address 1300 El Camino Real, Suite 100, Menlo Park, CA, USA, 94025
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology. Product candidate AN2-502998 Epetraborole.
22GF Score

Get the complete analysis for ANTX

Volatility is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.70
Price